Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01682668 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Subthalamic Nucleus, Akinesia and Parkinson's Disease

Study acronym: GB-MOV
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: May 2025 to Jul 2026
    • Study completion date: Aug 2025 to Aug 2026
    • Site details revised at 1 of 2 sites
    v9
  2. Enrollment target: 120 to 180
    • Primary completion date: May 2024 to May 2025
    • Study completion date: Aug 2024 to Aug 2025
    v8
  3. Enrollment target: 60 to 120
    • Primary completion date: Nov 2022 to May 2024
    • Study completion date: Feb 2023 to Aug 2024
    • Eligibility criteria expanded, about 483 words
    v7
  4. Primary completion date: Aug 2021 to Nov 2022
    • Study completion date: Dec 2021 to Feb 2023
    v6
  5. Study completion date: Sep 2021 to Dec 2021
    • Site contacts updated at 1 of 2 sites
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Sep 2018 to Aug 2021
    • Study completion date: Sep 2018 to Sep 2021
    • Site details revised at 1 of 2 sites
    v4
  2. Primary and study completion dates: Sep 2016 to Sep 2018v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2012 to Feb 2013
    • Study sites: 0 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This program aims to understand the role of the subthalamic nucleus in the control of the movement in healthy humans and patients with Parkinson's disease, how the STN dysfunction contributes to akinesia and how the STN stimulation improves motor signs in PD patients .
Trial Details
NCT Number NCT01682668
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)		 Parkinson's Disease
Related terms Parkinson Disease
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov